Vecuronium

證據等級: L5

預測適應症: 2 個

Vecuronium: From Neuromuscular Blockade to Insomnia

One-Sentence Summary

Vecuronium is a non-depolarizing neuromuscular blocking agent (NMBA) used intraoperatively to achieve skeletal muscle relaxation and facilitate endotracheal intubation during general anesthesia and ICU sedation. The TxGNN model predicts it may be effective for Insomnia, yet 0 clinical trials and 0 publications directly support this direction — the sole identified trial (NCT01431326) is an unrelated pediatric pharmacokinetics study with no insomnia relevance. The high TxGNN prediction score (99.34%) is assessed as a false-positive signal with no mechanistic basis.

Quick Overview

Item	Content
Original Indication	Neuromuscular blockade for surgical anesthesia and ICU muscle relaxation
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.34%
Evidence Level	L5
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacological knowledge, Vecuronium is a competitive antagonist at nicotinic acetylcholine receptors (nAChR) at the peripheral neuromuscular junction. It does not cross the blood-brain barrier and exerts no central nervous system activity whatsoever.

This prediction is assessed as a false positive. The pathophysiology of insomnia involves central sleep-wake regulatory pathways — GABAergic, histaminergic, orexinergic, and serotonergic systems — none of which intersect with Vecuronium’s peripheral skeletal muscle nAChR mechanism. Critically, administration of Vecuronium outside a fully monitored anesthesia environment causes complete respiratory muscle paralysis, requiring immediate intubation and mechanical ventilation. Applying it to an ambulatory insomnia patient would be immediately life-threatening.

The second-ranked prediction, Irritable Bowel Syndrome (IBS, TxGNN score 99.11%), is equally untenable. While nicotinic receptors exist in the enteric nervous system, Vecuronium’s high affinity for skeletal muscle nAChR subtypes means that any systemic dose sufficient to affect ENS function would first paralyze the diaphragm. Both predictions should be treated as algorithmic artifacts arising from indirect graph-topology associations rather than biological plausibility.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01431326	N/A	Completed	3,520	Pediatric multi-drug PK observation study collecting blood samples from children receiving standard-of-care drugs (including Vecuronium as a surgical/ICU agent). Study has no insomnia treatment objective; Vecuronium’s inclusion is purely incidental to its anesthetic use. Relevance grade: C — not supportive.

Note: This is the only trial identified. It is a broad pediatric pharmacokinetics surveillance study that happened to include Vecuronium among dozens of drugs. It does not represent any investigation of Vecuronium for insomnia.

Literature Evidence

Currently no related literature available.

Philippines Market Information

Vecuronium is currently not registered with the Philippine FDA. No product authorization records are on file.

Safety Considerations

Please refer to the package insert for safety information.

Critical Safety Alert: Vecuronium causes complete neuromuscular blockade including paralysis of the diaphragm and intercostal muscles. Any use outside a controlled surgical or ICU environment with full airway management capability constitutes an immediate, life-threatening risk. This pharmacological profile is a primary reason both repurposing predictions are non-viable.

Conclusion and Next Steps

Decision: Hold

Rationale: Vecuronium’s mechanism of action — peripheral nicotinic acetylcholine receptor blockade at the neuromuscular junction — has no conceivable connection to central sleep regulation or gastrointestinal motility in a clinically safe context. The TxGNN scores for both insomnia (99.34%) and IBS (99.11%) are false-positive signals driven by graph topology rather than pharmacological plausibility. Evidence level is L5 (model prediction only) across both indications, with zero supporting clinical trials, zero relevant literature, and zero Philippines regulatory presence.

To proceed, the following would be needed:

A mechanistic hypothesis demonstrating CNS or sleep-regulatory activity that does not require crossing the blood-brain barrier (currently no such pathway exists)
Identification of a Vecuronium derivative or prodrug form with CNS bioavailability and absent neuromuscular paralytic effect — this would constitute a structurally distinct new chemical entity, not repurposing
Preclinical in vivo sleep architecture data (polysomnography in rodent models) demonstrating any sedative or sleep-promoting effect
A safe administration route that decouples any putative CNS effect from respiratory muscle paralysis — currently pharmacologically impossible with this compound
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.